1RV Panoramica delle azioni Rhythm Pharmaceuticals, Inc. è un'azienda biofarmaceutica in fase di commercializzazione che si concentra sulle malattie neuroendocrine rare. Maggiori dettagli
Premi Analisi del rischio Non sono stati rilevati rischi per 1RV dai nostri controlli di rischio.
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Rhythm Pharmaceuticals, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Rhythm Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione US$54.50 Massimo di 52 settimane US$62.50 Minimo di 52 settimane US$32.20 Beta 2.14 Variazione di 1 mese 2.83% Variazione a 3 mesi -4.39% Variazione di 1 anno 22.20% Variazione a 3 anni 656.94% Variazione a 5 anni 215.03% Variazione dall'IPO 151.30%
Notizie e aggiornamenti recenti
Rhythm Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 26, 2025 Feb 14
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (Setmelanotide) for Patients as Young as 2 Years Old Dec 21
Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old Dec 03
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, Including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide Nov 19
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in the Lancet Diabetes & Endocrinology Nov 14
Third quarter 2024 earnings released: US$0.73 loss per share (vs US$0.76 loss in 3Q 2023) Nov 07 Vedi altri aggiornamenti
Rhythm Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 26, 2025 Feb 14
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (Setmelanotide) for Patients as Young as 2 Years Old Dec 21
Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old Dec 03
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, Including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide Nov 19
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in the Lancet Diabetes & Endocrinology Nov 14
Third quarter 2024 earnings released: US$0.73 loss per share (vs US$0.76 loss in 3Q 2023) Nov 07
Rhythm Pharmaceuticals Announces Five New Data Presentations At Obesityweek 2024 Nov 05
Rhythm Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 23
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old Aug 26
Second quarter 2024 earnings released: US$0.55 loss per share (vs US$0.82 loss in 2Q 2023) Aug 07
Forecast to breakeven in 2026 Aug 07
Rhythm Pharmaceuticals, Inc. Announces European Commission Expands IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old Jul 31 Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024
Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer Jul 08
Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index Jul 03
Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome Jun 29
New minor risk - Profitability May 09
No longer forecast to breakeven May 08
Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting May 08
First quarter 2024 earnings released: US$2.35 loss per share (vs US$0.92 loss in 1Q 2023) May 07
Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology Apr 30
Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024 Apr 28
Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 26
New major risk - Financial position Apr 04
Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management Apr 03 Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management Apr 02
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist Mar 27 Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals Mar 21
Full year 2023 earnings released: US$3.20 loss per share (vs US$3.48 loss in FY 2022) Feb 23
Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan Feb 23
New minor risk - Profitability Feb 09
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome Feb 07
Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Feb 01
New major risk - Share price stability Jan 23
Forecast to breakeven in 2026 Dec 31
Third quarter 2023 earnings released: US$0.76 loss per share (vs US$0.80 loss in 3Q 2022) Nov 09
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide) Nov 03
Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome Sep 07
Second quarter 2023 earnings released: US$0.82 loss per share (vs US$0.89 loss in 2Q 2022) Aug 02
Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 18
Rhythm Pharmaceuticals, Inc. Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023 Jun 19
Rhythm Pharmaceuticals, Inc. Announces Approval of IMCIVREE®? Setmelanotide Solution for Weight Management in Adult and Pediatric Patients May 09
First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.05 loss in 1Q 2022) May 03
Full year 2022 earnings released: US$3.48 loss per share (vs US$1.40 loss in FY 2021) Mar 02
Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome Jan 24
Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome Nov 22
Third quarter 2022 earnings released: US$0.80 loss per share (vs US$0.70 loss in 3Q 2021) Nov 09
Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology Nov 09
Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-Term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity At Obesityweek® and Plans to Initiate Phase 3 Trial in Early 2023 Nov 03
Rhythm Pharmaceuticals, Inc. Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA Nov 02
Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development Oct 07
Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022 Sep 20
Rhythm Pharmaceuticals, Inc. Announces European Commission Expands the Marketing Authorization for Imcivree(R) (Setmelanotide) Sep 07
Second quarter 2022 earnings released: US$0.89 loss per share (vs US$0.70 loss in 2Q 2021) Aug 03
Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome Jul 23
Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France Jul 21
NICE Recommends Rhythm’s IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency Jul 19
Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity Jul 13
Rhythm Pharmaceuticals, Inc. Announces That European Commission Authorized Variation for Imcivree (Setmelanotide) to Allow for Dosing in Patients with POMC or LEPR Deficiency with Renal Impairment Jun 23
Rhythm Pharmaceuticals, Inc. Announces FDA Approval of IMCIVREE for Use in Patients with Bardet-Biedl Syndrome Jun 17
Rhythm Pharmaceuticals Presents Initial Data from Long-Term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022 Jun 14
Rhythm Pharmaceuticals, Inc. Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome At the Pediatric Endocrine Society 2022 Virtual Annual Meeting May 04
Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity Apr 07
Forecast to breakeven in 2024 Feb 26
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome Feb 25 Rhythm Pharmaceuticals, Inc. Announces Executive Promotions
Rhythm Pharmaceuticals, Inc. Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS) Feb 17 Rhythm Pharmaceuticals, Inc. Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Patients with Genetic Obesity Disorder
High number of new directors Nov 04
Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain Sep 23
Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl and Alström Syndromes Sep 21
Chief Medical Officer Murray Stewart has left the company Sep 15
Rhythm Pharmaceuticals, Inc Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome Sep 10
Rhythm Pharmaceuticals, Inc. Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity Aug 05
Rhythm Pharmaceuticals, Inc. Announces European Commission Authorization of IMCIVREE Jul 25 Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Growth Index
Independent Director Todd Foley has left the company Jun 15
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency May 22
Chief Human Resources Officer has left the company May 01
Chairman recently bought €172k worth of stock Apr 01
Rhythm Pharmaceuticals, Inc. Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss At Up to Nine Months in Patients with Het Obesity on Setmelanotide At Endo 2021 Mar 21
Rhythm Pharmaceuticals, Inc. Announces Board Changes Mar 17
New 90-day low: €20.80 Mar 06
Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities Jan 29
New 90-day high: €31.20 Jan 23
New 90-day high: €26.80 Jan 07 Rendimenti per gli azionisti 1RV DE Biotechs DE Mercato 7D -1.8% -13.4% -1.3% 1Y 22.2% -17.3% 14.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 1RV ha superato il German Biotechs che ha restituito -17.3 % nell'ultimo anno.
Rendimento vs Mercato: 1RV ha superato il mercato German che ha restituito 14.9 % nell'ultimo anno.
Volatilità dei prezzi Is 1RV's price volatile compared to industry and market? 1RV volatility 1RV Average Weekly Movement 4.7% Biotechs Industry Average Movement 8.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.5%
Prezzo delle azioni stabile: 1RV non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di 1RV è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 2008 226 David Meeker rhythmtx.com
Rhythm Pharmaceuticals, Inc. è una società biofarmaceutica in fase di commercializzazione che si concentra sulle malattie neuroendocrine rare. Il candidato principale dell'azienda è IMCIVREE (setmelanotide), un recettore raro della melanocortina-4 per il trattamento dell'obesità da deficit di pro-opiomelanocortina (POMC), proproteina convertasi subtilisina/kexina di tipo 1, recettore della leptina (LEPR) e sindrome di Bardet-Biedl e Alström. È in fase di sperimentazione clinica di Fase 3 per il trattamento di obesità da deficit di POMC o LEPR eterozigote, obesità da deficit di coattivatore 1 dei recettori steroidei, obesità da deficit di SH2B1, obesità da deficit di recettore MC4 e altri disturbi di MC4R.
Mostra di più Rhythm Pharmaceuticals, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Rhythm Pharmaceuticals con la sua capitalizzazione di mercato? 1RV statistiche fondamentali Capitalizzazione di mercato €3.39b Guadagni(TTM ) -€249.07m Ricavi(TTM ) €107.15m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 1RV Conto economico (TTM ) Ricavi US$112.53m Costo del fatturato US$12.81m Profitto lordo US$99.72m Altre spese US$361.29m Guadagni -US$261.57m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
Feb 26, 2025
Utile per azione (EPS) -4.26 Margine lordo 88.61% Margine di profitto netto -232.45% Rapporto debito/patrimonio netto 71.5%
Come si è comportato 1RV nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/02/20 14:38 Prezzo dell'azione a fine giornata 2025/02/20 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github .
Fonti analitiche Rhythm Pharmaceuticals, Inc. è coperta da 18 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Tazeen Ahmad BofA Global Research Whitney Ijem Canaccord Genuity Corinne Johnson Goldman Sachs
Mostra 15 altri analisti 
